Professor for Cancer Immune TherapyInternational Center for Medical Technologies, in Baylor College of Medicine

2010.2

名古屋大学大学院　医学系研究科　准教授

2009.4 - 2017.5

Nagoya University

2009.4 - 2017.5

Associate Professor, Nagoya University Graduate School of Medicince

2007.5 - 2009.3

Associate Dean, Nagoya University Graduate School of Medicince

2007.5

Nagoya University   Associate Dean

2007.5

Chief Director, Division of Medical Support, Seto Reformatory, Seto, Japan

2004.4 - 2007.4

Assistant Professor, Department of Surgery II, Nagoya University School of Medicince

2004.4 - 2007.4

Department of Surgery II, Nagoya University Hospital, Nagoya, Japan

2003.10 - 2004.3

Research Fellow, MGH, Harvard Medical School, U.S.A.

2000.4 - 2003.9

名古屋大学医学部第二外科・医員

1996.4 - 2000.3

Department of Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan

1995.7 - 1996.3

Department of Surgery, Holy Spirit Hospital, Nagoya, Japan

1990.3 - 1995.6

Japan Society of Clinical Oncology

Japan Cancer Assiciation

The Japan Society of Gene Therapy

Japan Pancreas Society

Japan Surgical Association

Novel armed oncolytic HSV exhibits strong antitumor effects that lead to complete tumor regression

Abdelmoneim, MA; Naoe, Y; Eissa, IR; Aboalela, MA; Matsumura, S; Tanaka, M; Kasuya, H

CANCER SCIENCE   Vol. 114   page： 1855 - 1855   2023.2

Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model

Abdelmoneim, M; Eissa, IR; Aboalela, MA; Naoe, Y; Matsumura, S; Sibal, PA; Bustos-Villalobos, I; Tanaka, M; Kodera, Y; Kasuya, H

SCIENTIFIC REPORTS   Vol. 12 ( 1 ) page： 21570   2022.12

An international medical education perspective on training in child and adolescent psychiatry

Aleksic, B; Kasuya, H

ASIA-PACIFIC PSYCHIATRY   Vol. 14 ( 2 ) page： e12509   2022.6

Oncolytic HSV HF10 (canerpaturev, C-REV) promotes accumulation of CD8+PD-1-tumor-infiltrating T cells in a SCC model

Mohamed, AA; Eissa, IR; Mukoyama, N; Abdelmoneim, M; Naoe, Y; Matsumura, S; Bustosvillalobos, I; Ichinose, T; Miyajima, N; Morimoto, D; Tanaka, M; Fujimoto, Y; Sone, M; Kodera, Y; Kasuya, H

CANCER SCIENCE   Vol. 113   page： 526 - 526   2022.2

S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

Miyajima, N; Eissa, IR; Abdelmoneim, M; Naoe, Y; Ichinose, T; Matsumura, S; Bustos-Villalobos, I; Mukoyama, N; Morimoto, D; Shibata, M; Takeuchi, D; Tsunoda, N; Kikumori, T; Tanaka, M; Kodera, Y; Kasuya, H

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 4 ) page： 683 - 696   2021.11

Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8<SUP>+</SUP>PD-1<SUP>-</SUP> tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment

Eissa, IR; Mukoyama, N; Abdelmoneim, M; Naoe, Y; Matsumura, S; Bustos-Villalobos, I; Ichinose, T; Miyajima, N; Morimoto, D; Tanaka, M; Fujimoto, Y; Sone, M; Kodera, Y; Kasuya, H

INTERNATIONAL JOURNAL OF CANCER   Vol. 149 ( 1 ) page： 214 - 227   2021.7

C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells

Morimoto, D; Matsumura, S; Bustos-Villalobos, I; Sibal, PA; Ichinose, T; Naoe, Y; Eissa, IR; Abdelmoneim, M; Mukoyama, N; Miyajima, N; Tanaka, M; Kodera, Y; Kasuya, H

CELLS   Vol. 10 ( 6 )   2021.6

Problem-Based Learning in Child and Adolescent Psychiatry: A Perspective from Japan

Iwatsuki, J; Kondo, T; Takahashi, N; Takami, H; Nishigori, H; Bustos-Villalobos, I; Aleksic, B; Kasuya, H; Ban, NO; Yagi, T; Skokauskas, N

ADVANCES IN MEDICAL EDUCATION AND PRACTICE   Vol. 12   page： 1329 - 1335   2021

Continuing medical education during pandemic waves of COVID-19: Consensus from medical faculties in Asia, Australia and Europe.

Wong C, van den Broek W, Doody G, Fischer M, Leech M, De Ponti F, Gerbes A, Nishigori H, Lee YM, Frens M, Kasuya H, Bazzoli F, Hickel R, Lee HS, van Leeuwen JPTM, Mitchell C, Kadomatsu K, Atherton J, Chan F

MedEdPublish (2016)   Vol. 10   page： 64   2021

S-1 Facilitates C-REV Induced Anti-Tumor Efficacy in Triple Negative Breast Cancer Model

Kasuya, H; Naoe, Y; Matsumura, S; Bustos, I; Eissa, I; Mohamed, A; Tanaka, M

MOLECULAR THERAPY   Vol. 28 ( 4 ) page： 163 - 163   2020.4

Phase I study of the oncolytic viral immunotherapy agent canerpaturev (C-REV) with S-1 in patients with stage IV pancreatic cancer International journal

Hijioka, S; Ueno, M; Ioka, T; Hirooka, Y; Ohno, E; Okusaka, T; Maruki, Y; Kobayashi, S; Ashida, R; Yashika, J; Furuse, J; Ikeda, M; Kasuya, H; Tanaka, M; Hashimoto, Y

ANNALS OF ONCOLOGY   Vol. 30   2019.10

Results from phase I study of the oncolytic viral immunotherapy agent Canerpaturev (C-REV) in combination with gemcitabine plus nab-paclitaxel as first-line treatment of unresectable pancreatic cancer International journal

Hashimoto, Y; Hijioka, S; Hirooka, Y; Ohno, E; Ioka, T; Kobayashi, S; Okusaka, T; Maruki, Y; Yashika, J; Ashida, R; Furuse, J; Ikeda, M; Kasuya, H; Tanaka, M; Ueno, M

ANNALS OF ONCOLOGY   Vol. 30   page： 269 - +   2019.10

Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth Reviewed International journal

Wu, ZW; Ichinose, T; Naoe, Y; Matsumura, S; Villalobos, IB; Eissa, IR; Yamada, S; Miyajima, N; Morimoto, D; Mukoyama, N; Nishikawa, Y; Koide, Y; Kodera, Y; Tanaka, M; Kasuya, H

MOLECULAR THERAPY-ONCOLYTICS   Vol. 13   page： 107 - 115   2019.6

Joint Degree Program for Graduate Students at the Nagoya University Graduate School of Medicine Reviewed

Kasuya, H; Aleksic, B; Sumigama, S; Bustos, I; Hasegawa, H; Kasai, MP; Kobayashi, M; Samizo, Y

NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 2 ) page： 183 - 192   2019.5

STING is dispensable for low susceptibility for HF10 in pancreatic cell lines

Matsumura, S; Morimoto, D; Noe, Y; Ichinose, T; Tanaka, M; Kodera, Y; Kasuya, H

CANCER SCIENCE   Vol. 109   page： 1328 - 1328   2018.12

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.

Eissa IR, Bustos-Villalobos I, Ichinose T, Matsumura S, Naoe Y, Miyajima N, Morimoto D, Mukoyama N, Zhiwen W, Tanaka M, Hasegawa H, Sumigama S, Aleksic B, Kodera Y, Kasuya H

Cancers   Vol. 10 ( 10 )   2018.10

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer International journal

Hirooka Yoshiki, Kasuya Hideki, Ishikawa Takuya, Kawashima Hiroki, Ohno Eizaburo, Villalobos Itzel B., Naoe Yoshinori, Ichinose Toru, Koyama Nobuto, Tanaka Maki, Kodera Yasuhiro, Goto Hidemi

BMC CANCER   Vol. 18 ( 1 ) page： 596   2018.5

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity Reviewed

Yoshihiro Hotta, Hideki Kasuya, Itzel Bustos, Yoshinori Naoe, Toru Ichinose, Maki Tanaka, Yasuhiro Kodera

Oncolytic Virotherapy   Vol. 6   page： 31—38   2017.3

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.

Hotta Y, Kasuya H, Bustos I, Naoe Y, Ichinose T, Tanaka M, Kodera Y

Oncolytic virotherapy   Vol. 6   page： 31 - 38   2017

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials Reviewed

Ibrahim Ragab Eissa, Yoshinori Naoe, Itzel Bustos-Villalobos, Toru Ichinose, Maki Tanaka, Wu Zhiwen, Nobuaki Mukoyama, Taishi Morimoto, Noriyuki Miyajima, Hasegawa Hitoki, Seiji Sumigama, Branko Aleksic, Yasuhiro Kodera and Hideki Kasuya

Front. Oncol.   Vol. 7   page： 149   2017

Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft Reviewed

Gewen Tan, Hideki Kasuya, Tevfik Tolga Sahin, Kazuo Yamamura, Zhiwen Wu, Yusuke Koide, Yoshihiro Hotta, Toshio Shikano, Suguru Yamada, Akiyuki Kanzaki, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Yoko Nishikawa, Maki Tanaka, Naoko Tsurumaru, Toshie Kuwahara, Saori Fukuda, Toru Ichinose, Toyone Kikumori, Shin Takeda, Akimasa Nakao and Yasuhiro Korea

International Journal of Cancer   Vol. 136 ( 7 ) page： 1718–1730   2015.4

Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer Reviewed

Hideki Kasuya, Yasuhiro Kodera, Akimasa Nakao, Kazuo Yamamura, Tan Gewen, Wu Zhiwen, Yoshihiro Hotta, Suguru Yamada, Tsutomu Fujii, Saori Fukuda, Naoko Tsurumaru, Toshie Kuwahara, Toyone Kikumori, Yusuke Koide, Yasushi Fujimoto, Tsutomu Nakashima, Yoshiki Hirooka, Hiroshi Shiku, Maki Tanaka, Kazuto Takesako, Touru Kondo, Branko Aleksic, Hiroki Kawashima, Hidemi Goto, Yukihiro Nishiyama

Hepato-Gastroenterology   Vol. 61 ( 131 ) page： 599-605   2014.5

Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10. Reviewed

Yamamura K, Kasuya H, Sahin TT, Tan G, Hotta Y, Tsurumaru N, Fukuda S, Kanda M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Tanaka M, Kodera Y.

Ann Surg Oncol   Vol. 21 ( 2 ) page： 691-8   2014.2

Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer

Tevfik Tolga Sahin, Hideki Kasuya, Naohiro Nomura, Toshio Shikano, Tan Gewen, Akiyuki Kanzaki, Tsutomu Fujii, Takashi Sugae, Tsuneo Imai, Shuji Nomoto, Shin Takeda, Hiroyuki Sugimoto, Toyone Kikumori, Yasuhiro Kodera, Yukihiro Nishiyama, Akimasa Nakao

Cancer Gene Therapy   Vol. 19 ( 4 ) page： 229-237   2012.4

Antitumor efficacy of oncolytic herpes simplex virus adsorbed onto antigen-specific lymphocytes

Akiyuki Kanzaki, Hideki Kasuya, Kazuo Yamamura, Tevfik Tolga Sahin, Naohiro Nomura, Toshio Shikano, Takashi Shirota, Tan Gewen, Saori Fukuda, Makoto Misawa, Yoko Nishikawa, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Shuji Nomoto, Shin Takeda Yasuhiro Kodera, Akimasa Nakao

Cancer Gene Therapy   Vol. 19 ( 4 ) page： 292-298   2012.4

Prognostic implications of lymph node metastases in carcinoma of the body and tail of the pancreas.

Sahin TT, Fujii T, Kanda M, Nagai S, Kodera Y, Kanzaki A, Yamamura K, Sugimoto H, Kasuya H, Nomoto S, Takeda S, Morita S, Nakao A.

Pancreas     page： 40(7):1029-33   2011.10

Oncolytic Herpes Virus Induces Effective Anti-Cancer Immunity against Murine Colon Cancer.

Shirota T, Kasuya H, Kodera Y, Nishikawa Y, Shikano T, Sahin TT, Gewen T, Yamamura K, Kanzaki A, Yamada S, Fujii T, Sugimoto H, Nomoto S, Takeda S, Nakao A.

Hepatogastroenterology     page： 58(110-111)   2011.7

特集：膵疾患画像診断における最近の進歩 膵癌に対する術中超音波検査の最近の進歩

杉本博行,竹田　伸,野本周嗣,粕谷英樹,藤井　努,中尾昭公

膵臓   Vol. 26 ( 1 ) page： 66-71   2011.2

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer.

Nakao A, Kasuya H, Sahin TT, Nomura N, Kanzaki A, Misawa M, Shirota T, Yamada S, Fujii T, Sugimoto H, Shikano T, Nomoto S, Takeda S, Kodera Y, Nishiyama Y.

Cancer Gene Ther.     page： 18(3):167-75   2010.11

Medial prefrontal cortex-dorsal anterior cingulate cortex connectivity during behavior selection without an objective correct answer.

Nakao T, Osumi T, Ohira H, Kasuya Y, Shinoda J, Yamada J, Northoff G.

Neurosci Lett.     page： 4;482(3):220-4   2010.10

Clinical Trial of HF10 Oncolytic Virus Therapy for Advanced Pancreatic Cancer, Cancer Gene Ther. Reviewed

19. Akimasa Nakao, Hideki Kasuya, Tevfik Tolga Sahin, Naohiro Nomura, Akiyuki Kanzaki, Makoto Misawa, Takashi Shirota, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Toshio Shikano, Shuji Nomoto, Shin Takeda, Yasuhiro Kodera, Yukihiro Nishiyama

Cancer Gene Ther.     page： 2010, July   2010.7

High Therapeutic Potential for Systemic Delivery of a Liposome-conjugated Herpes Simplex Virus. Reviewed

20. Toshio Shikano, Hideki Kasuya, Tevfik Tolga Sahin, Naohiro Nomura, Akiyuki Kanzaki, Makoto Misawa, Yoko Nishikawa, Takashi Shirota, Suguru Yamada, Tsutomu Fujii, Hiroyuki Sugimoto, Naohito Kanazumi, Shuji Nomoto, Shin Takeda and Akimasa Nakao.

CCDT     page： 2010 [June Accepted]   2010.6

腫瘍溶解性ウィルス、HF10を使用したトランスレーショナルリサーチ Reviewed

17. 粕谷英樹、竹田　伸、今井常夫、野本周嗣、野村尚弘、杉本博行、三澤　真、山田　豪、神崎章之、藤井　努、Tevfik Tolga Sahin 、西山幸廣、中尾昭公

外科遺伝子治療フロンティア     page： 2010 1月   2010.1

膵癌の腫瘍溶解性ウイルス療法 Reviewed

18. 粕谷英樹、竹田　伸、今井常夫、野本周嗣、野村尚弘、杉本博行、三澤　真、山田　豪、神崎章之、藤井　努、Tevfik Tolga Sahin 、西山幸廣、中尾昭公

膵臓     page： 2010 1月   2010.1

Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms. Reviewed

16. Nakao A, Takeda S, Nomoto S, Kanazumi N, Kasuya H, Sugimoto H, Fujii T, Yamada S.

J Hepatobiliary Pancreat Surg.     page： 2009 Nov 3. [Epub ahead of print]   2009.11

Pancreatic cancer with distant metastases: a contraindication for radical surgery? Reviewed

15. Yamada S, Fujii T, Sugimoto H, Kanazumi N, Kasuya H, Nomoto S, Takeda S, Kodera Y, Nakao A

Hepatogastroenterology     page： 56(91-92):881-5   2009.5

Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. Reviewed

13. Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, Sugimoto H, Yamada S, Nakao A.

Hepatobiliary Pancreat Surg.     page： 2009 Apr 14   2009.4

The tumor suppressor NPRL2 in hepatocellular carcinoma plays an important role in progression and can be served as an independent prognostic factor. Reviewed

14. Otani S, Takeda S, Yamada S, Sakakima Y, Sugimoto H, Nomoto S, Kasuya H, Kanazumi N, Nagasaka T, Nakao A.

J Surg Oncol.     page： 2009 Mar 9   2009.3

Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases. Reviewed

12. Nomura N, Kasuya H, Watanabe I, Shikano T, Shirota T, Misawa M, Sugimoto H, Kanazumi N, Nomoto S, Takeda S, Nakao A.

Cancer Chemother Pharmacol.     page： 63(2): 321-30   2009.1

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Reviewed

10. Watanabe I, Kasuya H, Nomura N, Kanazumi N,Takeda S, Nomoto S, Shikano T, Shirota T, Sugimoto H, Nakao A.

Cancer Chemoth Pharm     page： 61(5):875-82   2008.4

Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Reviewed

Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A.

Br J Cancer.   Vol. 97 ( 9 ) page： 1260-1265   2007.11

Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Reviewed

11. Nomoto S, Kinoshita T, Kato K, Otani S, Kasuya H, Takeda S, Kanazumi N, Sugimoto H, Nakao A.

Br J Cancer.     page： 5;97(9):1260-5.   2007.11

Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis.

7. Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, Kasuya H, Kodera Y, Nagasaka T, Morita S, Nakao A.

Ann Surg     page： 246(2):254-8   2007.8

*Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy Reviewed

Kasuya H, Nishiyama Y, Nomoto S, Goshima F, Takeda S, Watanabe I, Nomura N, Shikano T, Fujii T, Kanazumi N, Nakao A.

Cancer Gene Ther   Vol. 14 ( 6 ) page： 533-542   2007.6

Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models. Reviewed

Shimoyama S, Goshima F, Teshigahara O, Kasuya H, Kodera Y, Nakao A, Nishiyama Y.

Hepatogastroenterology   Vol. 54 ( 76 ) page： 1038-1042   2007.6

*Oncolytic virus therapy--foreword Invited

Kasuya H, Takeda S, Shimoyama S, Shikano T, Nomura N, Kanazumi N, Nomoto S, Sugimoto H, Nakao A.

Curr Cancer Drug Targets   Vol. 7 ( 2 ) page： 123-125   2007.3

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Reviewed

Nakao A, Takeda S, Shimoyama S, Kasuya H, Kimata H, Teshigahara O, Sawaki M, Kikumori T, Kodera Y, Nagasaka T, Goshima F, Nishiyama Y, Imai T.

Curr Cancer Drug Targets.   Vol. 74 ( 29 ) page： 169-174   2007.3

Clinical application of replication competent mutant HSV in cancer therapy Invited

Kasuya H, Nakao A.

Nippon Rinsho   Vol. 64 ( 3 ) page： 335-339   2006.3

*The potential of oncolytic virus therapy for pancreatic cancer Reviewed

Kasuya H, Takeda S, Nomoto S, Nakao A.

Cancer Gene Ther   Vol. 12 ( 9 ) page： 725-736   2005.9

*Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies Reviewed

Kasuya H, Kuruppu DK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK.

Cancer Res   Vol. 65 ( 9 ) page： 3823-3827   2005.5

Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. Reviewed

Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM, Tanabe KK.

Cancer.   Vol. 101 ( 4 ) page： 869-877   2004.8

*Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen Reviewed

Kasuya H, Pawlik TM, Mullen JT, Donahue JM, Nakamura H, Chandrasekhar S, Kawasaki H, Choi E, Tanabe KK.

Cancer Res   Vol. 64 ( 7 ) page： 2561-2567   2004.4

Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Reviewed

Mullen JT, Kasuya H, Yoon SS, Carroll NM, Pawlik TM, Chandrasekhar S, Nakamura H, Donahue JM, Tanabe KK.

Ann Surg.   Vol. 236 ( 4 ) page： 502-512   2002.10

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Reviewed

Pawlik TM, Nakamura H, Mullen JT, Kasuya H, Yoon SS, Chandrasekhar S, Chiocca EA, Tanabe KK.

Cancer.   Vol. 95 ( 5 ) page： 1171-1181   2002.9

The potential of gene therapy in the treatment of pancreatic cancer Reviewed

Kasuya H, Nomoto S, Nakao A.

Drugs Today (Barc)   Vol. 38 ( 7 ) page： 457-464   2002.7

Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. Reviewed

Nakamura H, Kasuya H, Mullen JT, Yoon SS, Pawlik TM, Chandrasekhar S, Donahue JM, Chiocca EA, Chung RY, Tanabe KK.

J Clin Invest.   Vol. 109 ( 7 ) page： 871-882.   2002.4

Gene therapy for pancreatic cancer Reviewed

Kasuya H, Nomoto S, Kimata H, Harada A, Takeda S, Hayashi S, Nakao A.

Hepatogastroenterology   Vol. 48 ( 40 ) page： 957-961   2001.7

Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Reviewed

Yamada S, Takeda S, Fujii T, Nomoto S, Kanazumi N, Sugimoto H, Kasuya H, Kodera Y, Nagasaka T, Morita S, Nakao A.

Ann Surg   Vol. 246 ( 29 ) page： 254-258   2000.8

Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy. Reviewed

Kasuya H, Mizuno M, Yoshida J, Nishiyama Y, Nomoto S, Nakao A.

J Surg Oncol.   Vol. 74 ( 3 ) page： 214-218.   2000.7

Preserving gastroduodenal artery, pancreas head resection with second potion of duodenum intestine against mucin producing pancreastic tumor. Reviewed

Nakao A, Kaneko T, Takeda S, Inoue S, Nomoto S, Kasuya H, Koshikawa H

The Operation   Vol. 54   page： 21-26   2000

Three clinical records of respectable metastatic pancreastic tumor. Reviewed

Ishigure H, Kawase Y, Kanazumi N, Oshima K, Kotake K, Kasuya H, Sawada K, Nonami T, Harada A, Nakao A.

Japan Gastro-Intestinall Surgery Association (Japan)   Vol. 33   page： 1686   2000

Resection with preserving function of pancreass. Reviewed

Nakao A, Kaneko T, Takeda S, Inoue S, Nomoto S, Kasuya H, Koshikawa H.

Surgery (Japan)   Vol. 62   page： 416-421   2000

Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer Reviewed

Kasuya H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A.

J Surg Oncol   Vol. 72 ( 3 ) page： 136-141   1999.11

Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer. Reviewed

Nakao A, Oshima K, Takeda S, Kaneko T, Kanazumi N, Inoue S, Nomoto S, Kawase Y, Kasuya H.

Hepatogastroenterology.   Vol. 46 ( 29 ) page： 2974-2977   1999.9

Virall therapy using a replication-competennt HSV mutant (hrR3) for disseminated pancreastic cancer in mice.

Kasuya H, Nakao A, Kimata H, Nomoto S.

Journal of the Japan Pancreas Society   Vol. 14 ( 3 )   1999

Preserving gastroduodenal artery, pancreas head resection with second potion of duodenum intestine. Reviewed

Nakao A, Oshima K, Kaneko T, Takeda S, Kanazumi N, Kasuya H,

The Operation   Vol. 1   page： 33-38   1999

Postoperative delayed emptying in pylorus-preserving pancreatoduodenectomy using pancreaticogastrostomy: comparison of the reconstruction position. Reviewed

Kasuaya H, Nakao A, Nomoto S, Hosono J, Takeda S, Kaneko T, Takagi H.

Hepatogastroenterology.   Vol. 44 ( 15 ) page： 856-860   1997.5

次世代のがん治療薬・診断のための研究開発

粕谷 英樹、他98名（ Role： Joint author）

（株）技術情報協会  2016.2 

分子細胞治療フロンティア2015、chapter 3. 腫瘍溶解性ウイルスHF10: Combination Therapyの有用性

粕谷英樹、小寺泰弘、山田豪、後藤秀実、廣岡芳樹、川嶋啓揮、田中舞紀（ Role： Joint author）

飯田橋パピルス  2014.8 

肝胆膵疾患の診断と治療トピックス2006 (Oncolytic virus therapyを使用した膵癌への挑戦)

（ Role： Joint author）

株式会社アークメディア  2006.10 

ミレニアム消化器2000 (進行膵癌に対する集学的治療としての遺伝子治療)

粕谷英樹，木全秀人，中尾昭公（ Role： Joint author）

株式会社　日本メディカルセンター  2001.2 

Cancer therapy using mutant herpes virus (HF10)

2005.4 - 2006.3

Cooperative Research within an Affiliated University or Institute 

Cancer therapy against abdominal tumor using mutant herpes virus

2004.10 - 2005.3

Cooperative Research within an Affiliated University or Institute 

New strategy against disseminated pancreatic cancer using mutant herpes virus

1999.4 - 2001.3

Cooperative Research within an Affiliated University or Institute 

膵癌におけるAAVベクターを用いた遺伝子治療の基礎的研究

1996.4 - 1998.3

学内共同研究 

Development of innovative combination therapy of tumor antigen virus and TCR gene-modified T cells

Grant number：16K15611  2016.4 - 2018.3

Grants-in-Aid for Scientific Research  Grant-in-Aid for Challenging Exploratory Research

KASUYA Hideki

革新的な腫瘍抗原ウイルスとTCR遺伝子改変T細胞の併用療法の開発

2016.4 - 2018.3

科学研究費補助金  挑戦的萌芽研究

粕谷英樹

腫瘍溶解性ウィルスHF10吸着化リンパ球による新規治療法の開発

2013.4 - 2016.3

科学研究費補助金  基盤研究（B），課題番号：25293275

粕谷　英樹

腫瘍溶解性ウィルスによる新規消化管癌治療法の開発

2011.4 - 2014.3

科学研究費補助金  基盤研究（C），課題番号：23590922

森　義徳

トリプルアレイ法を応用した新規がん関連遺伝子の同定

2010.4 - 2013.3

科学研究費補助金  基盤研究（C），課題番号：22591427

野本　周嗣

EGCGによるAP-1を介した肝細胞癌発生抑制に関する研究

2010.4 - 2013.3

科学研究費補助金  基盤研究(C)

藤井努

リンパ球ヒッチハイク法による抗腫瘍ウイルス療法

2009.4 - 2012.3

科学研究費補助金  基盤研究（C），課題番号：21591662

粕谷　英樹

Inta venous injection of Oncolytic virus against liver metastasis

2008.4 - 2011.3

Grant-in-Aid for Scientific Research 

Influence of mutation type of p53-FGF-1 pathway in angiogenesis for cancerous tissue and metastasis

2007.4 - 2009.3

Grant-in-Aid for Scientific Research 

Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) for Cancer

2004.4 - 2007.3

Grant-in-Aid for Scientific Research